Abstract
The therapeutic options for patients with acute leukemia who relapse after the initial transplant include second bone marrow transplantation (2BMT) and conventional chemotherapy (CC). In this work, we conducted an analysis of published survival data and we evaluated the cost-effectiveness of 2BMT in comparison with CC. We retrieved survival information on 167 patients treated with 2BMT and 299 patients treated with CC. Survival figures were derived from individual patient data and were compared between 2BMT and CC. The mean lifetime survival (MLS) was estimated for each of the two patient cohorts using standard techniques of survival-curve extrapolation. The cost data of patients given 2BMT or CC were estimated from published data. Our analysis of individual survival data showed that 2BMT improved survival at levels of statistical significance (survival gain = 19.6 months per patient). Using an incremental cost of $90 000 per patient, the cost-effectiveness ratio of 2BMT in comparison with CC was calculated as $52 215 discounted dollars per discounted life year gained. Our results indicate that, in patients with acute leukemia who relapse after their first transplant, 2BMT significantly prolongs survival in comparison with CC and seems to have an acceptable cost-effectiveness profile.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Messori, A., Bosi, A., Bacci, S. et al. Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. Bone Marrow Transplant 23, 489–495 (1999). https://doi.org/10.1038/sj.bmt.1701600
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701600
Keywords
This article is cited by
-
Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation
Annals of Hematology (2017)
-
Management of relapse after allo-SCT for AML and the role of second transplantation
Bone Marrow Transplantation (2009)
-
Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant
Bone Marrow Transplantation (2008)
-
Event-free survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantation
Bone Marrow Transplantation (2007)
-
L’utilizzo di modelli decisionali per le valutazioni economiche dei farmaci in Italia: stato dell’arte e prospettive future
PharmacoEconomics Italian Research Articles (2007)